Keating Financial Advisory Services’s Apogee Therapeutics APGE Stock Holding History

Keating Financial Advisory Services’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$664	Buy	+5	New	+$450	﹤0.01%	2289

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Keating Financial Advisory Services's APGE Position: Q2 2026 in Review

Keating Financial Advisory Services opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 5 shares worth $664. The stake represents ﹤0.01% of the portfolio and ranks #2289 among its holdings.

288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Keating Financial Advisory Services held 5 shares of Apogee Therapeutics worth $664 as of Q2 2026.
Apogee Therapeutics was a new Keating Financial Advisory Services position in Q2 2026.
Apogee Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2289 holding.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.